Structural and Functional Assessment of Macula in Patients with High-Risk Proliferative Diabetic Retinopathy Submitted to Panretinal Photocoagulation and Associated Intravitreal Bevacizumab Injections: A Comparative, Randomised, Controlled Trial

2013 ◽  
Vol 230 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Rony Carlos Preti ◽  
Lisa Mariel Vasquez Ramirez ◽  
Mário Luiz Ribeiro Monteiro ◽  
David E. Pelayes ◽  
Walter Yukihiko Takahashi
Keyword(s):  
Diabetic Retinopathy ◽  
High Risk ◽  
Randomised Controlled Trial ◽  
Proliferative Diabetic Retinopathy ◽  
Functional Assessment ◽  
Controlled Trial ◽  
Intravitreal Bevacizumab ◽  
Panretinal Photocoagulation ◽  
Randomised Controlled

scholarly journals Microinvasive pars plana vitrectomy versus panretinal photocoagulation in the treatment of severe non-proliferative diabetic retinopathy (the VIP study): study protocol for a randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e043371
Author(s):  
Wenbin Zheng ◽  
Shida Chen ◽  
Xiaohu Ding ◽  
Kunbei Lai ◽  
Sainan Xiao ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Randomised Controlled Trial ◽  
Pars Plana Vitrectomy ◽  
Controlled Trial ◽  
Diabetic Macular Oedema ◽  
Panretinal Photocoagulation ◽  
Progression Rate ◽  
Thickness Change ◽  
Pars Plana ◽  
Randomised Controlled

IntroductionDiabetic retinopathy (DR) is the main cause of adult visual impairment worldwide. Severe non-proliferative DR (sNPDR) is an important clinical intervention stage. Currently, panretinal photocoagulation (PRP) is the standard treatment for sNPDR. However, PRP alone cannot completely prevent NPDR progression. One explanation might be that PRP does not remove the detrimental vitreous that plays an important role in DR progression. Microinvasive pars plana vitrectomy (PPV) was shown to be a safe and effective method to treat late-stage proliferative DR (PDR) by completely removing the pathological vitreous. However, whether PPV is effective in controlling sNPDR remains unknown. In this trial, we aim to compare the effectiveness of microinvasive PPV with that of PRP for sNPDR progression control.Methods and analysisThis single centre, parallel group, randomised controlled trial aims to evaluate the clinical efficacy of microinvasive PPV in preventing the progression of sNPDR compared with PRP. A total of 272 adults diagnosed with sNPDR will be randomised 1:1 to the microinvasive PPV and PRP groups. The primary outcome is the disease progression rate, calculated as the rate of sNPDR progressed to PDR from baseline to 12 months after treatment. The secondary outcomes include the change in best-corrected visual acuity, re-treatment rate, diabetic macular oedema occurrence, change in central retinal thickness, change in the visual field, cataract occurrence and change in the quality of life.Ethics and disseminationThe Ethics Committee of Zhongshan Ophthalmic Center approved this study (2019KYPJ108). The results will be presented at scientific meetings and submitted for publication to peer-reviewed journals.Trial registration numberNCT04103671.

Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial

2015 ◽  
Vol 235 (1) ◽  
pp. 34-41 ◽  
Author(s):  
João Figueira ◽  
Rufino Silva ◽  
José Henriques ◽  
Paulo Caldeira Rosa ◽  
Inês Laíns ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
High Risk ◽  
Proliferative Diabetic Retinopathy ◽  
Controlled Trial ◽  
Combined Treatment ◽  
Panretinal Photocoagulation ◽  
Complete Regression ◽  
Duration Of Treatment ◽  
Intravitreal Ranibizumab ◽  
Rescue Treatment

Purpose: To compare the efficacy and safety of intravitreal ranibizumab (IVR) in monotherapy or associated with panretinal photocoagulation (PRP) versus conventional PRP, for high-risk proliferative diabetic retinopathy (PDR) without vitreoretinal traction. Procedures: Multicenter randomized trial, with 3 treatment arms: PRP versus IVR alone and PRP + IVR combined treatment. Follow-up was performed at months 3, 6 and 12. Results: Thirty-five subjects were randomized and 32 used for analysis. Complete regression of neovessels elsewhere occurred in 100% (PRP + IVR), 75% (IVR) and 69.2% (PRP) and for neovessels of the disk in 44.4% (PRP + IVR), 37.5% (IVR) and 30.8% (PRP). During the 1-year duration of treatment, there was no need for laser rescue treatment in IVR-treated eyes. Conclusions: This trial suggests that the use of IVR is safe and may have a beneficial effect in the treatment of eyes with high-risk PDR. Message: Ranibizumab appears to have a place in the treatment of PDR.

Sign in / Sign up

Export Citation Format

Share Document